A double-blind, placebo controlled study of the effect of the specific histamine H1-receptor antagonist, terfenadine, in chronic severe asthma.

British Journal of Clinical Pharmacology ◽

10.1111/j.1365-2125.1995.tb05727.x ◽

1995 ◽

Vol 39 (6) ◽

pp. 671-675 ◽

Author(s):

R. Wood-Baker ◽

R. Smith ◽

ST Holgate

Keyword(s):

Receptor Antagonist ◽

Severe Asthma ◽

Controlled Study ◽

H1 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Histamine H1 Receptor ◽

H1 Receptor Antagonist

Download Full-text

Pharmacological studies with SK&F 93944 (temelastine), a novel histamine H1-receptor antagonist with negligible ability to penetrate the central nervous system

British Journal of Pharmacology ◽

10.1111/j.1476-5381.1986.tb10199.x ◽

1986 ◽

Vol 87 (3) ◽

pp. 569-578 ◽

Author(s):

E. Ann Brown ◽

R. Griffiths ◽

Carol A. Harvey ◽

D.A.A. Owen

Keyword(s):

Central Nervous System ◽

Nervous System ◽

Receptor Antagonist ◽

H1 Receptor ◽

Histamine H1 Receptor ◽

Pharmacological Studies ◽

The Central Nervous System ◽

H1 Receptor Antagonist

Download Full-text

PM308. A phase 3, multicenter randomized double blind placebo controlled study of the opioid receptor antagonist –Odelepran the treatment of alcohol addiction.

The International Journal of Neuropsychopharmacology ◽

10.1093/ijnp/pyw041.308 ◽

2016 ◽

Vol 19 (Suppl_1) ◽

pp. 10-10 ◽

Keyword(s):

Receptor Antagonist ◽

Opioid Receptor ◽

Alcohol Addiction ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Opioid Receptor Antagonist

Download Full-text

Faculty Opinions recommendation of Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738625631.793590472 ◽

2021 ◽

Author(s):

Kaei Nasu

Keyword(s):

Receptor Antagonist ◽

Dose Response ◽

Hormone Receptor ◽

Gonadotropin Releasing Hormone ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Releasing Hormone ◽

Gonadotropin Releasing Hormone Receptor

Download Full-text

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study

Fertility and Sterility ◽

10.1016/j.fertnstert.2020.07.055 ◽

2020 ◽

Author(s):

Yutaka Osuga ◽

Yoshifumi Seki ◽

Masataka Tanimoto ◽

Takeru Kusumoto ◽

Kentarou Kudou ◽

...

Keyword(s):

Receptor Antagonist ◽

Dose Response ◽

Hormone Receptor ◽

Gonadotropin Releasing Hormone ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Releasing Hormone ◽

Gonadotropin Releasing Hormone Receptor

Download Full-text

Preclinical Pharmacology of Desloratadine, a Selective and Nonsedating Histamine H1 Receptor Antagonist

Arzneimittelforschung ◽

10.1055/s-0031-1300213 ◽

2011 ◽

Vol 50 (04) ◽

pp. 345-352 ◽

Author(s):

William Kreutner ◽

John Hey ◽

John Anthes ◽

Allen Barnett ◽

Simon Young ◽

...

Keyword(s):

Receptor Antagonist ◽

H1 Receptor ◽

Histamine H1 Receptor ◽

Preclinical Pharmacology ◽

H1 Receptor Antagonist

Download Full-text

Simultaneous determination of the histamine H1-receptor antagonist ebastine and its two metabolites, carebastine and hydroxyebastine, in human plasma using high-performance liquid chromatography

Journal of Chromatography B Biomedical Sciences and Applications ◽

10.1016/s0378-4347(00)00494-1 ◽

2001 ◽

Vol 757 (1) ◽

pp. 173-179 ◽

Author(s):

Michiaki Matsuda ◽

Yasuyuki Mizuki ◽

Yoshiaki Terauchi

Keyword(s):

High Performance Liquid Chromatography ◽

Liquid Chromatography ◽

Receptor Antagonist ◽

Simultaneous Determination ◽

Human Plasma ◽

High Performance ◽

H1 Receptor ◽

Histamine H1 Receptor ◽

H1 Receptor Antagonist

Download Full-text

Temelastine, a novel histamine H1 -receptor antagonist, does not induce oxidative hepatic enzyme activity in man

European Journal of Drug Metabolism and Pharmacokinetics ◽

10.1007/bf03189863 ◽

1987 ◽

Vol 12 (1) ◽

pp. 65-69

Author(s):

C. De Mey ◽

I. Meineke ◽

H. Wesche

Keyword(s):

Enzyme Activity ◽

Receptor Antagonist ◽

Hepatic Enzyme ◽

H1 Receptor ◽

Histamine H1 Receptor ◽

Hepatic Enzyme Activity ◽

H1 Receptor Antagonist

Download Full-text

In vivo biliary excretion and in vitro cellular accumulation of thyroxine by rats or cultured rat hepatocytes treated with a novel histamine H1-receptor antagonist

Archives of Toxicology ◽

10.1007/bf01977630 ◽

1990 ◽

Vol 64 (6) ◽

pp. 474-481 ◽

Author(s):

Alan Poole ◽

Deborah Pritchard ◽

Richard B. Jones ◽

Linda Catto ◽

Thomas Leonard

Keyword(s):

Receptor Antagonist ◽

Biliary Excretion ◽

Rat Hepatocytes ◽

H1 Receptor ◽

Cellular Accumulation ◽

Histamine H1 Receptor ◽

Cultured Rat Hepatocytes ◽

H1 Receptor Antagonist

Download Full-text

Pharmacokinetic Optimisation of Histamine H1-Receptor Antagonist Therapy

Clinical Pharmacokinetics ◽

10.2165/00003088-199121050-00005 ◽

1991 ◽

Vol 21 (5) ◽

pp. 372-393 ◽

Author(s):

F. Estelle ◽

R. Simons ◽

Keith J. Simons

Keyword(s):

Receptor Antagonist ◽

H1 Receptor ◽

Antagonist Therapy ◽

Histamine H1 Receptor ◽

H1 Receptor Antagonist

Download Full-text

Nebulized dehydroepiandrosterone-3-sulfate improves asthma control in the moderate-to-severe asthma results of a 6-week, randomized, double-blind, placebo-controlled study

Allergy and Asthma Proceedings ◽

10.2500/aap.2010.31.3384 ◽

2010 ◽

Vol 31 (6) ◽

pp. 461-471 ◽

Author(s):

Sally E. Wenzel ◽

Cynthia B. Robinson ◽

Joanne M. Leonard ◽

Reynold A. Panettieri

Keyword(s):

Asthma Control ◽

Severe Asthma ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text